Literature DB >> 29023996

Effect of sex difference in clinical presentation (stable coronary artery disease vs unstable angina pectoris or non-ST-elevation myocardial infarction vs ST-elevation myocardial infarction) on 2-year outcomes in patients undergoing percutaneous coronary intervention.

Xiao-Fang Tang1, Ying Song1, Jing-Jing Xu1, Yuan-Liang Ma1, Jia-Hui Zhang1, Yi Yao1, Chen He1, Huan-Huan Wang1, Ping Jiang1, Lin Jiang1, Ru Liu1, Zhan Gao2, Xue-Yan Zhao2, Shu-Bin Qiao2, Bo Xu2, Yue-Jin Yang2, Run-Lin Gao2, Jin-Qing Yuan2.   

Abstract

OBJECTIVE: To determine whether there is a difference in 2-year prognosis among patients across the spectrum of coronary artery disease undergoing percutaneous coronary intervention (PCI).
METHODS: We analyzed all consecutive patients undergoing PCI at a single center from 1/1-12/31/2013. Clinical presentations were compared between sexes according to baseline clinical, angiographic, and procedural characteristics and 2-year (mean 730 ± 30-day) outcomes.
RESULTS: We grouped 10 724 consecutive patients based on sex and clinical presentation. Among patients with ST-elevation myocardial infarction (STEMI), rates of all-cause death (6.7% vs 1.4%) and cardiac death (3.8% vs 1.1%) were significantly higher in women than in men (P < 0.05), but these rates did not differ between men and women with stable coronary artery disease (SCAD) and non-ST-elevation acute coronary syndrome ((NSTE-ACS). Incidence of major bleeding was greater than in men only in those women presenting with ACS. After multivariable adjustment, female sex was not an independent predictor of outcomes in STEMI (hazard ratio [HR] for all-cause death: 1.33, 95% confidence interval [CI]:0.52-3.38; P = 0.55; HR for cardiac death: 0.69, 95%CI: 0.23-2.09, P = 0.51], but was still an independent predictor of bleeding in STEMI (HR: 3.53, 95%CI: 1.26-9.91, P = 0.017).
CONCLUSION: Among STEMI patients, women had worse 2-year mortality after PCI therapy, but female sex was not an independent predictor of mortality after adjustment for baseline characteristics. In STEMI patients, women were at higher bleeding risk than men after PCI, even after multivariable adjustment.
© 2017, Wiley Periodicals, Inc.

Entities:  

Keywords:  clinical outcomes; clinical presentation; percutanous coronary intervention; sex difference

Mesh:

Year:  2017        PMID: 29023996     DOI: 10.1111/joic.12451

Source DB:  PubMed          Journal:  J Interv Cardiol        ISSN: 0896-4327            Impact factor:   2.279


  4 in total

1.  Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.

Authors:  Emily S Lau; Eugene Braunwald; David A Morrow; Robert P Giugliano; Elliott M Antman; C Michael Gibson; Benjamin M Scirica; Erin A Bohula; Stephen D Wiviott; Deepak L Bhatt; Marc P Bonaca; Christopher P Cannon; KyungAh Im; Jianping Guo; Marc S Sabatine; Michelle L O'Donoghue
Journal:  Circulation       Date:  2021-02-15       Impact factor: 29.690

2.  Serum Levels of Cystatin C, N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP), and Cardiac Function in Patients with Unstable Angina Pectoris.

Authors:  Manyun Long; Lang Li
Journal:  Med Sci Monit       Date:  2020-03-13

3.  Gender differences in clinical outcomes of acute myocardial infarction undergoing percutaneous coronary intervention: insights from the KAMIR-NIH Registry.

Authors:  Myunhee Lee; Dae-Won Kim; Mahn-Won Park; Kyusup Lee; Kiyuk Chang; Wook Sung Chung; Tae Hoon Ahn; Myung Ho Jeong; Seung-Woon Rha; Hyo-Soo Kim; Hyeon Cheol Gwon; In Whan Seong; Kyung Kuk Hwang; Shung Chull Chae; Kwon-Bae Kim; Young Jo Kim; Kwang Soo Cha; Seok Kyu Oh; Jei Keon Chae; Ji-Hoon Jung
Journal:  J Geriatr Cardiol       Date:  2020-11-28       Impact factor: 3.327

4.  Contemporary sex differences in mortality among patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis.

Authors:  Ziwei Xi; Hong Qiu; Tingting Guo; Yong Wang; Jianan Li; Yang Li; Jianfeng Zheng; R Gao
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.